Open Heart

JANUARY 27, 2022

Objectives (1) To evaluate the prevalence and hospitalisation rate of COVID-19 infections among patients with dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) in the Royal Brompton and Harefield Hospital Cardiovascular Research Centre (RBHH CRC) Biobank. (2) To evaluate the indirect impact of the pandemic on patients with cardiomyopathy through the Heart Hive COVID-19 study. (3) To assess the impact of the pandemic on national cardiomyopathy-related hospital admissions.

COVID-19 52

COVID-19 Cardiomyopathy Hospital Heart Disease 52

Dr. Sanjay Gupta

JANUARY 25, 2022

The York Press A YORK heart specialist says he believes many Long Covid patients may actually have a condition called POTS – and could benefit from treatments used for patients with the syndrome. Dr Sanjay Gupta, a consultant cardiologist at York Hospital, is an expert in POTS, or postural tachycardia syndrome. The condition can leave sufferers debilitated, constantly exhausted, and sometimes unable even to walk.

POTS 52

POTS Hospital Chest Pain Blood Pressure 52

Open Heart

JANUARY 27, 2022

Objective We previously reported early-onset atrial fibrillation (AF) associated genetic loci among a Korean population. We explored whether the AF-associated single-nucleotide polymorphisms (SNPs) selected from the Genome-Wide Association Study (GWAS) of an external large cohort has a prediction power for AF in Korean population through a convolutional neural network (CNN).

Atrial Fibrillation 52

Atrial Fibrillation 52

Open Heart

JANUARY 27, 2022

Background Early recognition of ST-segment elevation myocardial infarction (STEMI) is needed for timely cardiac monitoring and reperfusion therapy. Methods Three anonymously linked New Zealand national datasets (July 2016–November 2018) were used to assess the utilisation of ambulance transport in STEMI cases, the concordance between ambulance initial clinical impressions and hospital STEMI diagnoses, and the association between initial paramedic clinical impressions and 30-day mortality.

Myocardial Infarction 52

Myocardial Infarction STEMI Hospital 52

Open Heart

JANUARY 26, 2022

Objective To estimate the population prevalence and treatable burden of severe aortic stenosis (AS) in the UK. Methods We adapted a contemporary model of the population profile of symptomatic and asymptomatic severe AS in Europe and North America to estimate the number of people aged ≥55 years in the UK who might benefit from surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI).

Stenosis 52

Stenosis Aortic Aortic valve 52

Open Heart

JANUARY 24, 2022

Aims Left atrial (LA) enlargement is an independent risk factor for atrial fibrillation (AF). Interestingly, some athletes have increased risk of AF, which may be linked to LA enlargement; however, little is known about the relationship between LA enlargement and AF risk at moderate-level physical activity (PA). We aimed to explore the associations between PA, LA size and risk of incident AF, and if PA can attenuate the risk of AF with LA enlargement.

Atrial Fibrillation 40

Atrial Fibrillation Risk Factors Hospital 40

Open Heart

JANUARY 24, 2022

Non-rheumatic aortic stenosis (AS) is among the most common valvular diseases in the developed world. Current guidelines support aortic valve replacement (AVR) for severe symptomatic AS, which carries high morbidity and mortality when left untreated. In contrast, moderate AS has historically been thought to be a benign diagnosis for which the potential benefits of AVR are outweighed by the procedural risks.

Stenosis 40

Stenosis Aortic Aortic valve Outcomes 40